By Chris Wack
Editas Medicine Inc. said Monday that it is undertaking a portfolio reprioritization and research-and-development realignment, which volition see cutting 20% of its staff.
The institution said its R&D efforts would narrow, focusing connected hemoglobinopathies and in-vivo discovery, allowing it to prosecute and make programs it believes person maximum probabilities of technical, regulatory, and commercialized success.
As a effect of the strategical reprioritization, Editas Medicine's headcount is being reduced by astir 20%, which is expected to widen the company's currency runway into 2025.
The institution is prioritizing assets allocation towards EDIT-301, its pb objective programme for the attraction of terrible sickle compartment illness and transfusion-dependent beta thalassemia. Editas is besides discontinuing interior investments successful its inherited retinal illness programs. Editas Medicine said it would question partnerships for further improvement of its IRD programs.
The institution is restructuring its probe enactment into 2 divisions. Drug Discovery would absorption connected in-vivo people identification, therapeutic plus creation, and translational research. Advanced Technology would absorption connected in-vivo targeted integration and targeted delivery.
In transportation with the reprioritization of Editas Medicine's portfolio, Chief Scientific Officer Mark S. Shearman is expected to measurement down from his relation and depart the company, effectual March 31. Editas Medicine has begun a hunt for a caller technological chief.
Write to Chris Wack astatine chris.wack@wsj.com
English (US)